NUWE
Nuwellis, Inc.
$0.1400
0.00%
$1.8M
No data for this timeframe.
Vol
Market Cap$1.8M
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$5.4K
Inst. Activity1 buys / 0 sells
Reddit Sentiment50° Neutral
SEC Reports9
Press Releases5
Exchange Nasdaq·Sector Electromedical & Electrotherapeutic Apparatus·Inc. DE·CIK 0001506492·Prev Close $0.1400
Recent Activity
Jun 10, 2026
SEC
Nuwellis closed a registered public offering on June 8, 2026, raising approximately $6.0 million in gross proceeds by is
8-K — Impact 7/10
Jun 10, 2026
contract
Nuwellis Expands Collaboration with Major South Carolina Healthcare System to Install New Aquadex SmartFlow® Devices at One of its Children’s Hospitals
South Carolina healthcare provider also upgrades to latest Aquadex devices at its two locations that
Jun 8, 2026
SEC
Nuwellis priced a dilutive emergency capital raise via a 424B4 prospectus supplement, offering up to 1,903,338 shares of
424B4 — Impact 7/10
Jun 4, 2026
SEC
Nuwellis, Inc. filed Amendment No. 2 to its S-1 registration statement for a best-efforts standby equity offering of up
S-1/A — Impact 7/10
Apr 28, 2026
Insider
WALLER GREGORY D was granted 6,744 shares
Director
Apr 28, 2026
Insider
Feldshon Archelle Georgiou was granted 6,744 shares
Director
Apr 28, 2026
Insider
Emerson Martin J was granted 6,744 shares
Director
Inst.
BANK OF AMERICA CORP — DOUBLED
11 shares ($19.00)
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 13, 2024 | Roth MKM | REITERATE | Buy → Buy |
| Jul 29, 2024 | Roth MKM | INITIATE | Buy |
| Nov 8, 2023 | Ladenburg Thalmann | DOWNGRADE | Buy → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.68 ▼ -41.7% | $-0.68 — $-0.68 | 99% YoY | 1 |
| Next Q | $-0.39 ▼ -18.2% | $-0.39 — $-0.39 | -170% YoY | 1 |
| Current FY | $-2.29 ▼ -35.5% | $-2.29 — $-2.29 | 91% YoY | 1 |
| Next FY | $-0.63 ▲ +32.3% | $-0.63 — $-0.63 | 72% YoY | 1 |
Latest Reports
BEARISH
8-K
7/10
Nuwellis closed a registered public offering on June 8, 2026, raising approximately $6.0 million in gross proceeds by is
Jun 10, 2026
NEUTRAL
Press
4/10
Nuwellis announced an expansion of its collaboration with a South Carolina healthcare system, adding Aquadex SmartFlow d
Jun 10, 2026
BEARISH
424B4
7/10
Nuwellis priced a dilutive emergency capital raise via a 424B4 prospectus supplement, offering up to 1,903,338 shares of
Jun 8, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| CITIGROUP INC | $5.4K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 28, 2026 | WALLER GREGORY | A | $0.00 |
| Apr 28, 2026 | Feldshon Archelle | A | $0.00 |
| Apr 28, 2026 | Emerson Martin | A | $0.00 |
| Apr 28, 2026 | McDonald David | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
1 institutional holders with $5.4K total value (5,126 shares) as of 2026-Q1. Top holders: CITIGROUP.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | CITIGROUP INC | 5,126 | $5.4K | 100.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 5 | 11 | +120.0% | $19.00 | 2025-Q4 |
| UBS Group AG | DOUBLED | 4,150 | 78,910 | +1801.4% | $17.4K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 23,236 | 4,150 | -82.1% | $3.9K | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 11 | 37 | +236.4% | $41.00 | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 4 | 11 | +175.0% | $13.00 | 2024-Q3 |
4 unique insiders with 4 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 28, 2026 | WALLER GREGORY D | Director | AWARD | 6,744 | — | — |
| Apr 28, 2026 | Feldshon Archelle Georgiou | Director | AWARD | 6,744 | — | — |
| Apr 28, 2026 | Emerson Martin J | Director | AWARD | 6,744 | — | — |
| Apr 28, 2026 | McDonald David | Director | AWARD | 6,744 | — | — |
9 SEC filing reports analyzed. Sentiment: 0 bullish, 6 bearish, 1 mixed, 2 neutral. Avg impact: 5.9/10.
BEARISH
8-K
7/10
Nuwellis closed a registered public offering on June 8, 2026, raising approximately $6.0 million in
Jun 10, 2026
BEARISH
424B4
7/10
Nuwellis priced a dilutive emergency capital raise via a 424B4 prospectus supplement, offering up to
Jun 8, 2026
BEARISH
S-1/A
7/10
Nuwellis, Inc. filed Amendment No. 2 to its S-1 registration statement for a best-efforts standby eq
Jun 4, 2026
BEARISH
S-1/A
7/10
Nuwellis, Inc. filed Amendment No. 1 to its S-1 registration statement for a best-efforts standby eq
May 29, 2026
BEARISH
S-1
7/10
Nuwellis, Inc. filed an S-1 registration statement for a best-efforts standby equity offering of up
May 22, 2026
BEARISH
PRESS-RELEASE
7/10
Nuwellis reported Q1 2026 revenue of $2.4M (beat consensus of $2.1M by 14%) but EPS of -$2.09 signif
May 12, 2026
NEUTRAL
PRESS-RELEASE
2/10
Nuwellis announced it will report Q1 2026 results on May 12, 2026. The press release contains no fin
May 5, 2026
NEUTRAL
8-K
3/10
Nuwellis, Inc. settled a legal dispute with E.F. Hutton & Co. for $204,000 related to alleged breach
Apr 24, 2026
MIXED
8-K
6/10
Nuwellis appointed two new independent directors, Martin J. Emerson and David A. McDonald, to streng
Feb 26, 2026
NEUTRAL
4/10
Nuwellis announced an expansion of its collaboration with a South Carolina healthcare system, adding
Jun 10, 2026
BEARISH
7/10
Nuwellis closed a public offering of common stock, pre-funded warrants, and Series C/D warrants, rai
Jun 9, 2026
BEARISH
8/10
Nuwellis priced a public offering of 20M shares (plus warrants) at $0.30 per unit for ~$6M gross pro
Jun 5, 2026
NEUTRAL
2/10
Nuwellis highlighted a pediatric case study presented at ISHLT 2026 showing the use of its Aquadex S
Apr 29, 2026
MIXED
6/10
Nuwellis reported mixed Q4 and full-year 2025 results: Q4 revenue rose 4% YoY to $2.4 million with s
Mar 10, 2026
Historical analyst distribution (last covering-analyst action Aug 2024): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.68 | $-0.68 | $-0.68 | 98.9% | -41.7% | 0↑ 1↓ | $0.0B | — | 1 |
| Next Q 2026-09-30 |
$-0.39 | $-0.39 | $-0.39 | -169.6% | -18.2% | 0↑ 1↓ | $0.0B | — | 1 |
| Current FY 2026-12-31 |
$-2.29 | $-2.29 | $-2.29 | 91.0% | -35.5% | 0↑ 1↓ | $0.0B | 19.3% | 1 |
| Next FY 2027-12-31 |
$-0.63 | $-0.63 | $-0.63 | 72.5% | +32.3% | 1↑ 0↓ | $0.0B | 12.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.680 | |
| 7d ago | $-0.480 | -0.200 |
| 30d ago | $-0.480 | -0.200 |
| 60d ago | $-0.480 | -0.200 |
| 90d ago | $-0.520 | -0.160 |
2 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 13, 2024 | Roth MKM | REITERATE | Buy | Buy |
| Jul 29, 2024 | Roth MKM | INITIATE | — | Buy |
| Nov 8, 2023 | Ladenburg Thalmann | DOWNGRADE | Buy | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Nov 5, 2024 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 10, 2026
contract
Nuwellis Expands Collaboration with Major South Carolina Healthcare System to Install New Aquadex SmartFlow® Devices at One of its Children’s Hospitals
South Carolina healthcare provider also upgrades to latest Aquadex devices at its two locations that already use the technology <pre>South Carolina he
Jun 9, 2026
offering
Nuwellis Announces Closing of $6.0 Million Registered Public Offering
<p>MINNEAPOLIS , June 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for
Jun 5, 2026
offering
Nuwellis Announces Pricing of $6 Million Public Offering
<p>MINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for
May 14, 2026
other
Nuwellis Announces Successful Completion of FDA Pre-Submission 510(k) Meeting to Expand Aquadex Label
Proposal would extend treatment access to pediatric patients weighing 5 kg and above <pre>Proposal would extend treatment access to pediatric patients
May 12, 2026
earnings
Nuwellis, Inc. Announces First Quarter 2026 Financial Results
<p align="justify">MINNEAPOLIS, May 12, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering
May 11, 2026
earnings_calendar
NUWE Q1 2026 Earnings Scheduled — 2026-05-11
May 5, 2026
earnings
Nuwellis, Inc. To Announce First Quarter 2026 Financial Results on May 12, 2026
<p align="justify">MINNEAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering
Apr 29, 2026
fda
Nuwellis Highlights Case Study Featuring Precision Ultrafiltration Therapy in Pediatric Cardiorenal Care at ISHLT 2026 Annual Meeting
Poster presentation showcased continued advancement of Aquadex therapy in pediatric applications, underscoring continued need for adoption in fluid ma
Apr 23, 2026
routine
Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat
Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth 530 <pre>Medical technology company to showcase Aqua
Apr 16, 2026
other
Nuwellis Welcomes Back Three Former Team Members to Accelerate Commercial and Clinical Momentum
<p align="justify">MINNEAPOLIS, April 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to deliveri
Apr 9, 2026
other
Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services
<p align="justify">MINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to deliveri
Apr 7, 2026
other
Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory
Strategic expansion of field coverage enhances hospital engagement and increases access to Aquadex® therapy across the region <pre>Strategic expansion
Mar 31, 2026
other
Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone
Pediatric footprint expands to 47 centers nationwide, including six of the nation’s top 10 children’s hospitals <pre>Pediatric footprint expands to 47
Mar 10, 2026
earnings
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results
<p align="justify">MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to deliveri
Mar 10, 2026
earnings_calendar
NUWE Q4 2025 Earnings After Market Close — 2026-03-10